With a small grant from the RAND REACH Center and a team of volunteers from the National University of Natural Medicine, we are conducting a literature review of existing data on how the most commonly consumed species of psychedelic mushrooms, Psilocybe cubensis, effects human health. The goal of the project is to identify gaps in our knowledge through the lens of the National Center for Complementary and Integrative Health (NCCIH) guidelines for natural product research. The findings will be published in a peer reviewed journal and a subsequent grant application will aim to help us better understand these mushrooms.
The goal of this project is to find if providing deep meditative experiences while teaching meditation will help people to develop meditation practices. The long term effects of meditation practice has some similarities to the temporary effects of psychedelic experiences, including those induced by low-dose ketamine, namely the supression of the default mode network. Converserly, those who would benefit most from meditation practices are often those who struggle the hardest to develop a practice which does not have quick and immediate results. Thus, a very small dose of ketamine (or other short acting psychedelic like DMT) which is less psychedelic and more meditative, may provide participants a taste of what deeper states of meditation have to offer.
Right now we are seeking funding for a feasibility study to simply develop the protocol. In later studies we hope to include imaging studies to better understand neurological effects and to introduce blinding and randomization to an active control group.
Generic ketamine itself is off-patent and cheap as a medicine which, among other things, means no pharmaceutical company is incentivised to run clinical trials necessary to convince the FDA to approve it (or insurance companies to cover it) for the treatment of psychiatric conditions. Johnson & Johnson got Spravato approved by the FDA by patenting half of the ketamine molecule (called an enantiomer) so they can charge an outrageous price for the drug even though studies have shown it is no better than regular (racemic) ketamine for the treatment of depression. However, the Spravato model offers no psychological support. We would like to do a randomized clinical trial that compares Spravato to ketamine-assisted psychotherapy. Even if the costs are similar due to paying psychotherapists for the additional support, we feel this is a more holistic model of care that benefits patients and practitioners over pharmaceutical companies. We believe we can run this study with as little as $50,000, but we could make it more robust with $100,000. This project would be done in collaboration with KAPstone Clinics and the National University of Natural Medicine.
We want to do a bigger and better version of our feasibility study that includes affinity groups for people of color, Spanish speakers, LGBTQ, and both urban and rural populations with facilitators with those identities. We intend to use a step-wedge design where some participants are put on a waitlist for a few months as a comparator group, but after their waiting period, they also get to receive the treatment. This will greatly improve the validity of our outcomes, and we hope, bring policy makers one step closer to considering insurance coverage for this powerful treatment that could lead to greatly enhanced accessibility. We estimate this study will cost $500,000. This project would be a partnership with the Sheri Eckert Foundation and the National University of Natural Medicine.
Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
Ketamine-Assisted Psychotherapy for Antisocial Personality Disorder: A Case Report
Hicks, M. R., Zwickey, H., & Bradley, R. (2025). Ketamine-Assisted Psychotherapy for Antisocial Personality Disorder: A Case Report. Journal of Psychoactive Drugs, 1–7. https://doi.org/10.1080/02791072.2025.2449911
Viewpoints
Vitalism and Naturopathy in Psychedelic Medicine
Is Psychedelic Therapy Integrative Medicine?
Shamanism as a clinical intervention: A scoping review
Hicks, M. & Harris, R. Shamanism as a clinical intervention: A scoping review. Journal of Restorative Medicine 15, 54–62 (2025).
Naturopathic medical student empathy and burnout: A preliminary study
Expectancy Effect in Three Mind-Body Clinical Trials